Mountain Valley MD Proceeding With Pre-Clinical Cancer Trials, Files Related Cancer Patent
Share this article Share this article TORONTO, May 3, 2021 /PRNewswire/ - Mountain Valley MD Holdings Inc. (the " Company" or " MVMD") (CSE: MVMD) (FRA: 20MP) (OTCQB: MVMDF) is pleased to announce that the Company has filed a novel cancer adjuvant patent and is proceeding with pre-clinical trials with third-party cancer Contract Research Organizations (CROs) in triple-negative breast cancer, metastatic melanoma, and lung carcinoma. Summary MVMD files cancer patent for direct intratumoral injection, intravenously, infusions or instillations as adjuvants for broad chemotherapeutic to immunot...
Source: prnewswire.com